

be required to receive copies of the patent applications.

### Methods of Use of Nitrite Therapy

M. Gladwin (CC), R. Cannon (NHLBI), A. Schechter (NIDDK), C. Hunter (CC), R. Pluta (NINDS), E. Oldfield (NINDS), D. Kim-Shapiro (EM), R. Patel (EM), D. Lefler (EM), G. Power (EM). U.S. Patent Application 60/484,959 filed 09 July 2003 (DHHS Reference No. E-254-2003/0-US-01). U.S. Patent Application 60/511,244 filed 14 Oct 2003 (DHHS Reference No. E-254-2003/1-US-01). PCT Applications filed 09 July 2004 (DHHS Reference Nos. E-254-2003/2-PCT-01 and E-254-2003/3-PCT-01).

*Licensing Contact:* Susan Carson; (301) 435-5020; [carsonsu@mail.nih.gov](mailto:carsonsu@mail.nih.gov).

Different therapeutic classes of compounds that are able to increase blood flow and act as vasodilators have been used to treat a wide variety of disease indications including cardiovascular and respiratory diseases. Endothelium-derived factors, such as nitric oxide (NO), play a crucial role in the maintenance of vascular homeostasis, and NO-enhancing compounds have been administered alone or in combination with an approved pharmaceutical agent in order to provide an effective therapeutic treatment. Many of these therapies are very costly and there remains a strong need for an affordable treatment. Recent scientific work by the inventors provided evidence that the anion nitrite represents a circulating and tissue storage form of nitric oxide whose bioactivation is mediated by the nitrite reductase activity of deoxyhemoglobin [Nature Medicine 2003 9(12):1498-1505].

NIH scientists and their collaborators have now shown that low, physiological and non-toxic concentrations of sodium nitrite are able to increase blood flow and produce vasodilation by infused and nebulised routes of administration. Proof of concept data has been obtained in animal models for myocardial and hepatic ischemia and reperfusion injury, in a neonate lamb model for neonatal pulmonary hypertension, and in a primate model for prevention of delayed cerebral vasospasm following sub-arachnoid hemorrhage. The implications of these results point to the use of nitrite as a potential cost-effective platform therapy for a wide variety of disease indications characterized broadly by constricted blood flow or tissue hypoxia. Available for licensing are method of use claims for nitrite salt formulations directed to conditions associated with high blood pressure, decreased blood flow or hemolytic disease (E-254-2003/2) and for the

treatment of specific conditions such as pulmonary hypertension, cerebral artery vasospasm and hepatic, cardiac or brain ischemia-reperfusion injury (E-254-2003/3).

Dated: August 14, 2004.

### Steven M. Ferguson,

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-19301 Filed 8-23-04; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institutes; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* National Cancer Institute Director's Consumer Liaison Group, NCI's Director's Consumer Liaison Group.

*Date:* September 13-15, 2004.

*Time:* 10 a.m. to 4 p.m.

*Agenda:* Open; Review of DCLG Working Group; Dep Dir Panel; NCI Orientation; Cancer Survivorship, Reducing Cancer Health Disparities; Discussion with NCI Director/Next Steps; Update for NCI Director; Director's Remarks/Discussion; Recognition of Former DCLG Members; Facilitating Dialogue.

*Place:* Holiday Inn Select, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Nancy Caliman, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institute, 6116 Executive Boulevard, Suite 220, MSC8324, Bethesda, MD 20892, (301) 496-0307, [calimann@mail.nih.gov](mailto:calimann@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 16, 2004.

### LaVerne Y. Stringfield,

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-19295 Filed 8-23-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Eye Institute Special Emphasis Panel, Review of Nanomedicine Roadmap.

*Date:* September 1-2, 2004.

*Time:* 7:30 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Richard S. Fisher, PhD, Scientific Review Administrator, National Eye Institute, Division of Extramural Research, 5635 Fishers Lane, Bethesda, MD 20892, (301) 451-2020, [rfisher@nei.nih.gov](mailto:rfisher@nei.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: August 16, 2004.

### LaVerne Y. Stringfield,

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-19292 Filed 8-23-04; 8:45 am]

**BILLING CODE 4140-01-M**